参考文献/References:
[1] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S)[J]. Lancet,1994,344(8934):1383-1389.
[2] Gupta A,Smith DA.The 2013 American College of Cardiology/American Heart Association guidelines on treating blood cholesterol and assessing cardiovascular risk:a busy practitioners guide[J]. Endocrinol Metab Clin North Am,2014,43(4):869-892.
[3] Reiner Z.Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients:a clinical update[J].Nutr Metab Cardiovasc Dis,2013,23(9):799-807.
[4] TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung,and Blood Institute,Grosby J,et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease[J]. N Engl J Med,2014,371(1):22-31.
[5] Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al.Loss-of-function mutations in APOC3 and risk of ischemic vascular disease[J]. N Engl J Med,2014,371(1):32-41.
[6] Sehayek E,Eisenberg S.Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway[J]. J Biol Chem,1991,266(27):18259-18267.
[7] Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection[J]. Science,2008,322(5908):1702-1705.
[8] Crawford DC, Dumitrescu L, Goodloe R, et al. Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the Epidemiologic Architecture for Genes Linked to Environment(EAGLE)Study[J]. Circ Cardiovasc Genet,2014,7(6):848-853.
[9] Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans[J]. PLoS Biol,2006,4(4):e113.
[10] Luc G, Fievet C, Arveiler D,et al.Apolipoproteins C-Ⅲ and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur'Infarctus du Myocarde[J]. J Lipid Res,1996,37(3):508-517.
[11] Kawakami A, Aikawa M, Alcaide P, et al. Apolipoprotein CⅢ induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells[J]. Circulation,2006,114(7):681-687.
[12] Olivieri O, Martinelli N, Baroni M, et al. FactorⅡactivity is similarly increased in patients with elevated apolipoprotein CⅢ and in carriers of the factorⅡ20210A allele[J]. J Am Heart Assoc,2013,2(6):e000440.
[13] Holmberg R, Refai E, Höög A, et al. Lowering apolipoprotein CⅢ delays onset of type 1 diabetes[J]. Proc Natl Acad Sci USA,2011,108(26):10685-10689.
[14] Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CⅢ, and E,and risk of recurrent coronary events in the Cholesterol and Recurrent Events(CARE)trial[J]. Circulation, 2000,102(16):1886-1892.
[15] Jensen MK, Rimm EB, Furtado JD,et al. Apolipoprotein C-Ⅲ as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease[J].J Am Heart Assoc,2012, 1(2). pii: jah3-e000232.
[16] Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease:role of high-density lipoprotein-proteome remodeling[J].Circulation,2013,127(8):891-904.
[17] Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-Ⅲ and the risk of coronary heart disease[J]. Circulation,2011,124(19):2065-2072.
[18] Graham MJ, Lee RG, Bell TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-Ⅲ reduces plasma triglycerides in rodents, nonhuman primates, and humans[J]. Circ Res,2013, 112(11):1479-1490.
[19] Gaudet D,Brisson D,Tremblay K,et al,Targeting APOC3 in the familial chylomicronemia syndrome[J].N Engl J Med,2014,371(23):2200-2206.
[20] Gaudet D, Alexander VJ, Baker BF, et al.Antisense inhibition of apolipoprotein C-Ⅲ in patients with hypertriglyceridemia[J].N Engl J Med, 2015,373(5):438-447.